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 An aspartate transcarbamoylase (ATCase) gene from Bordetella pertussis was 
amplified by PCR and ligated into pT-ADV for expression in Escherichia coli.  This 
particular ATCase (pyrB) was an inactive gene found adjacent to an inactive 
dihydroorotase (DHOase) gene (pyrC’).  This experiment was undertaken to determine 
whether this pyrB gene was capable of expression alone or if it was capable of expression 
only when cotransformed with a functional pyrC’. When transformed into E. coli TB2 
pyrB-, the gene did not produce any ATCase activity.  The gene was then co-transformed 
into E. coli TB2 pyrB- along with a plasmid containing the pyrC’ gene from 
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Bordetella pertussis.  Bordetella pertussis is a Gram-negative, strictly aerobic 
coccobacillus.  B. pertussis causes whooping cough in humans, which is marked by its 
distinct coughing symptom.  B. pertussis is still a problem today in unvaccinated and 
under-vaccinated populations.  The acellular form of the vaccine has proved to be less 
than successful (Weiss 1992).  Clearly a new and readily acceptable acellular vaccine is 
needed to control B. pertussis infection.  This pathogen is difficult to culture outside the 
host in the laboratory with the result that little is known about its genomic or biochemical 
properties.  What is known is that B. pertussis shows a great deal of genetic variation as 
well as variable genetic expression within single strains (Stibitz, et al 1999) 
Infection by B. pertussis may be divided into three stages, catarrhal, paroxysmal, 
and convalescence, based on the symptoms exhibited by the subject.  The catarrhal stage 
begins five to 10 days after exposure, and is marked by cold or flu-like symptoms.  At 
this stage isolation of the pathogen is easiest, presumably due to the high concentration of 
organisms in the airways.  This also accounts for the greater contagiousness of the subject 
at this stage.  The paroxysmal stage is most often associated with the B. pertussis 
infection.  At this stage the characteristic Whooping” occurs as the infected subject 
follows a cough with an intake of air through swollen passage ways.  During this stage 
the subject is most vulnerable to secondary infections.  The final stage of B. pertussis 
infection is convalescence, and is characterized by a decrease in the acuteness of 
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symptoms.  Once this final stage of the disease is reached, obtaining bacterial 
cultures of B. pertussis from the subject becomes difficult if not impossible.  This 
suggests that the organism has disappeared from the host (Weiss 1992). 
The pyrimidine biosynthetic pathway is responsible for the de novo synthesis of 
pyrimidine nucleotides.  This pathway is extremely conserved, with little variation in 
reaction order between organisms (Figures 1-3).  The regulation of this pathway in 
different organisms is by comparison quite diverse.   The first committed step in the 
pyrimidine pathway is the conversion of the precursors carbamoylphosphate and 
aspartate into carbamoylaspartate and Pi by the enzyme aspartate transcarbamoylase 
(ATCase)  (Figures 1-3).  Though ATCase is a highly conserved feature of the pathway, 
variations have been reported in both its regulation and size.  These variations have led to 
a classification system proposed by Bethell & Jones (1969). 
Class A ATCases are dodecameric with a molecular mass of approximately 450-
500 kDa (Figure 4).  The genes for class A enzymes were originally cloned and 
sequenced from Pseudomonas aeruginosa (Vickrey 1993) and P.  putida (Schurr 1992 
and Schurr  et al. 1995).  Class A genes have more recently been detected in a number of 
pseudomonads and pseudomonad-like organisms (Kenny et al. 1996, Linscott 1996).  P. 
putida and P. aeruginosa  ATCases are dodecamers of six 36.4 kDa pyrB polypeptides 
and six 44.2 kDa pyrC’  polypeptides.  These organisms have a functional ATCase 
(pyrB), nonfunctional DHOase (pyrC’) and  a functional DHOase (pyrC) which catalyzes 
the next step in the pyrimidine pathway (Schurr et al. 1995).  More recently, Brichta 
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Salvage genes & enzymes: 
cdd:  Cytidine deaminase 
cmk: Cytidine 5’-monophosphate kinase 
cod:  Cytosine deaminase 
nmg: Nucleoside monophosphate  glycosylase 
upp:  Uracil phosphoribosyltransferase 
udk:  Uridine kinase 
udp:  Uridine phosphorylase 
rihA: Ribonucleoside hydrolase A 
rihB: Ribonucleoside hydrolase B      COP
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P. aeruginosa.  These DHOases combined, constitute three pyrC sequences in this 
organism.  To date, no other organism has been shown to contain more than two pyrC 
sequences. 
Class B enzymes are dodecamers like those of class A, but they have a smaller 
molecular mass.  The archetypal organism for class B is E. coli with an ATCase of  about 
310 kDa (Weber 1968).  The holoenzyme is formed by six identical pyrB polypeptides 
organized into two trimers and six identical regulatory pyrI  (DHOase) polypeptides 
organized into three dimers (Figure 4).  This arrangement is the rule among all enteric 
and class B ATCase bacteria (Wild et al 1980)   
Class C enzymes are found in all Gram positive bacteria.  The enzyme is 100 kDa 
in size and is typified by that found in Bacillus subtilis.  The C type enzymes consist of 
three catalytic polypeptide chains with a molecular mass of 102 kDa (Figure 4).  The 
class C enzymes lack the associated pyrI of the class B enzymes (Brabson & Switzer 
1975).  
Recently the ATCase of Burkholderia cepacia was determined to be unlike that of the 
pseudomonads with which it had previously been classified.  It was proposed that the 
organism be reclassified into a new taxonomic group (Li & West 1995).  This led to an 
investigation of genomic databases to locate organisms that shared homology with the B. 
cepacia ATCase genes.  The search results disclosed that B. pertussis had a similar 
ATCase arrangement (ATC1), with a holoenzyme of about 600 kDa exhibits ATCase and 
DHOase activities.  Elsewhere on the B. pertussis chromosome, a second  ATCase gene 
(pyrB) was found adjacent to a DHOase gene (pyr C’), neither of which showed any 
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expressed activity.  The pyrB of the pyrBC’  Pseudomonas-like complex in B. pertussis 
was chosen for investigation.  This pyrB gene product forms trimers that do not display 
activity.  In all Pseudomonas species studied to date, the gene requires the pyrC’ product 
to be active.  In B. pertussis the same complex is seen, but it is not active.  I have 
investigated whether the pyrB alone is capable of encoding a functional ATCase.  To that 
end the pyrB gene was amplified by PCR and ligated into pT-ADV (Table 1).  The 
resulting recombinant plasmid, pBPATC2 (Table 1) with the pyrB gene, was transformed 
into E. coli TOP10F’. The Blue/White screening method described by the pT-ADV 
manufacturer Clontech, was used.  The recombinant plasmid was digested with EcoRI 
and examined by gel electrophoresis.  The desired clone was initially selected based on 
the inserted DNA fragment size (≈ 1.2kbp).  DNA sequencing was used for final 
confirmation.  pBPATC2  was then transformed into E. coli TB2 pyrB- and the resultant 
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METHODS 
 
 Chemicals.  Ampicillin monosodium salt, agarose, dibasic potassium phosphate, 
monobasic potassium phosphate, ammonium sulfate, sodium citrate, magnesium sulfate, 
thiamine, dextrose, Tris, chloride, ammonium persulfate, sodium dodecyl sulfate, and 
EDTA disodium salt were all provided by Fisher Scientific Co.  Luria-Bertani medium , 
sodium chloride, potassium chloride, monobasic sodium phosphate, dibasic sodium 
phosphate, bromophenol blue, charcoal agar, Bordet Gengou agar base, and granulated 
agar were provided by Difco laboratories.  Agarose, low melting point agarose, sarkosyl, 
aspartate, carbamylphosphate, 5-bromo-4-chloro-3-indoyl-b-D-galactopyranoside (X-
gal), isopropyl-B-thio-galactopyranoside (IPTG), proteinase K, bisacrylamide, 
acrylamide and calcium chloride dihydrate were provided by Sigma Chemical Company.  
Glycerol, glacial acetic acid, ethanol and sucrose were provided by EM Science.  BamHI, 
BamHI Buffer, EcoRI, EcoRI Buffer, Hind III, NEB Buffer 2, and 1kb DNA ladder, were 
all provided by New England Biolabs.  PCR was performed using the Advan Taq Plus 
PCR kit from Clontech Laboratories.  Plasmid mini and midi preparation Quantum Prep 
kits were provided by Bio-Rad.   
 Type II H2O was generated by a Barnstead NANOpure ultrapure water system.  
All Type II  H2O was then autoclaved. 
 The AdvanTAge  PCR cloning kit was provided by Clontech and included the 
pT-ADV vector, linearized control DNA template control promoters 1 & 2, 10X buffered 
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dNTP mix, T4 DNA ligase, 10X ligation buffer, sterile water, bet-mercaptoethanol 
TOP10F’ E. coli competent cells, SOC medium, and pUC18. 
Bacterial Strains and Plasmids.  The bacterial strains and plasmids used in this 
study are listed in table 1.   
Agarose Minigel Electrophoresis.  Agarose gel electrophoresis was used to 
confirm the size as well as presence of DNA throughout this research.  A minigel was 
prepared by using the Fisher Biotech Electrophoresis Midi and Mini-Horizontal system. 
A 1% agarose gel was made with 1X TAE (diluted 10X TAE 48.4g Tris, 11.4ml glacial 
acetic acid, 7.5g EDTA, 800ml H2O, adjusted to pH 8.0), and Fisher Scientific agarose, 
heated until an even liquid was apparent, and poured into a prepared Fisher Biotech tray 
with a comb inserted.  The gel was allowed to cool and was then submerged in 1X TAE.  
The comb was then removed.  5X loading dye (25g glycerol, 0.125g bromophenol blue, 
0.5ml of 0.5M EDTA, and ddH2O to 50ml total volume)  in 2µl aliquots was mixed by 
pipeting with 10µl of DNA.  10µl of this sample was loaded into the wells while the gel 
was submerged.  A New England Biolabs 1kb DNA ladder was loaded into the first well, 
or the center well, depending on the number of DNA samples.  Electrophoresis was 
performed using an EC Apparatus Corporation EC3000P series 90 programmable power 
unit at 100 volts for 1 hour and 30 minutes or 2 hours and 30 minutes for the larger gel.  
The gel was later stained in ethidium bromide at 0.5µg/ml and destained by rinsing with 
water for 5 minutes.  Gels were examined using a Bio-Rad Gel Doc 1000 and pictures 
were printed with a Sony UP-D860 Digital Graphic Printer. 
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Table 1 Strains and Plasmids 
Strain or plasmid Description of relevant phenotype Source  
   
Strains   
   
E. coli   
TOP10F' AmpR lacZβ Clontech 
TB2 ∆pyrB- 
Bethesda Research Laboratories, 
Inc. 
   
Bordetella pertussis  
Tohama I BP348 bvg- Mark Peppler, University of Alberta 
   
Plasmids   
PT-ADV AmpR lacZα Clontech 
pBPATC2 AmpR ∆lacZα pyrB This study 















Media and Growth Conditions.  E. coli was grown in Luria-Bertani (LB) broth 
with aeration and LB agar and minimal medium agar plates at 37°C.  Appropriate 
antibiotics were added to the medium as follows:  cells containing the pT-ADV plasmid, 
ampicillin (100 µg/ml).  B. pertussis strains were grown in Stainer-Scholte medium and 
Bordet Gengou agar plates.   The E. coli minimal medium contained 10.5g K2HPO4, 4.5g 
KH2PO4, 1.0g (NH4)2SO4, 0.5g Na3 citrate.  These chemicals were dissolved one at a 
time in 500ml of ddH2O and autoclaved.  After cooling they were combined with a 
second preparation of 15g agar, 1ml 1M MgSO4, 1ml 1000X thiamine, and 10ml 
20%(w/v) glucose, which had also been autoclaved in 500ml of ddH2O.  When growing 
the E. coli pyrimidine  auxotroph (TB2), the minimal medium was supplemented with 
uracil (50µg/ml) and arginine (50µg/ml).   
Stainer-Scholte medium was made in two parts (A and B).  Part A was prepared 
as follows:  0.24g L-proline, 0.67g L-glutamic acid, 2.5g NaCl, 0.5g KH2PO4, 0.2g KCl, 
0.1g MgCl2 · 6H2O, 0.02g CaCl2, and 6.1g Tris were dissolved in 800ml of ddH2O and 
the pH was adjusted to 7.6 using 2.5N HCl.  The final volume was adjusted to one liter 
and the solution was autoclaved for 20 minutes and cooled to room temperature.  Part B 
is a 10X stock solution and was prepared by dissolving 0.4g L-cysteine, 0.2g ascorbic 
acid, 0.04g nicotinic acid, 1g glutathione, and 0.1g FeSO4 · 7H2O in 100ml ddH2O.  This 
solution was then filter sterilized.  Part B was added to part A at ratio of 1:100.  20% 
sterile casamino acids were added as growth enhancer after parts A and B were combined  
(Stainer 1970, Imaizumi et al. 1983).  
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 Bordet Gengou/10% rabbit blood agar plates was made by adding 30g of Bordet 
Gengou Agar Base with 1 liter of ddH2O with 10g of glycerol.  The ingredients were 
heated to boiling to suspend the contents completely.  This mixture was sterilized in the 
autoclave and cooled to 45°C before rabbit blood was added to make the final 
concentration 10%.  
 Chromosomal isolation.  An isolated colony of B. pertussis Tohama BP348 was 
taken form a 48 hour growth on Bordet Gengou/10% rabbit blood agar plate and 
emulsified in 2mls of Stainer Sholte medium.  100µl aliquots were spread on 15 plates of 
Bordet Gengou/10% rabbit blood plates.  These plates were incubated for 48 hours at 
35°C.  The resulting lawn growth was scraped from the agar plates with a sterile glass 
slide and placed in a sterile disposable 50ml Falcon® tube with 26ml of Tris-buffered 
saline (TBS) and vortexed to evenly suspend the cells.  The cells were centrifuged for 5 
minutes at 4,000xg at 4°C and washed with 25mls of TBS and centrifuged once more.  
The wash was then repeated.  The resulting pellet was then suspended in 2.5 ml of TBS 
and placed in a 37°C waterbath.  2.5ml of 1% sarkosyl/100 mM EDTa pH8.0 was 
preheated to 50°C and added and the 5ml mixture was placed in a 50°C waterbath.  500µl 
of a 20mg/ml proteinase K solution were added and left overnight for digestion.  The 
digested protein was removed by repeated extractions with equal volumes of 
chloroform/isoamyl alcohol (24:1) until all precipitated proteins were removed.  One 
final protein extraction was affected by using an equal volume of buffered phenol pH 8.0, 
chloroform, isoamyl alcohol (25:24:1).  Residual traces of organic solvents were removed 
by extraction with an equal volume of diethyl ether.  Two and one half volumes of cold 
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100% ethanol (-20°C) were slowly added to create two phases.  The genomic DNA was 
collected by spooling onto a glass rod.  The spooled DNA was rinsed in 70% ethanol and 
drained well.  The genomic DNA was then dissolved in 5ml of 1 X TE buffer.  5µl of a 
10mg/ml solution of RNase was then added.  The DNA was then examined on a 1% 
agarose gel to determine size and quantity.  
 Polymerase chain reaction.  Amplification of the pyrB gene from B. pertussis 
was achieved with polymerase chain reaction (PCR).    The primers were constructed by 
Intergrated DNA Technologies to amplify the pyrB gene.  The PCR mixture contained 
1µl of isolated chromosomal DNA, 80ng of forward primer, 80ng of reverse primer, 5µl 
of 10x PCR buffer, 2µl 100 mM dNTPs, 2µl of Taq polymerase, and sterile ddH2O to 
bring the mixture up to 50µl.  The cycling for the PCR were: 94°C for 3 minutes, 30 
cycles of 94 °C for 30 seconds and 65°C for 30 seconds, 72°C for 5 minutes, and hold at 
4°C.  DNA was checked on 1% agarose gel for size and quantity. 
 PCR product and vector ligation preparation.  The PCR product was prepared 
for ligation by placing 20ul of the product into a 0.5ml microfuge tube with 2µl of 3M Na  
Acetate and 66µl of 100% ethanol.  The contents were mixed by pipetting and placed on 
dry ice for 15 min.  After 15 minutes the tube was centrifuged at 4°C at 6,702xg for 10 
minutes.  The ethanol was removed and 1ml of 70% ethanol was added.  The tube was 
inverted once to mix and placed on dry ice for 5 minutes.  The tube was then spun at 4°C 
at 6,702xg for 5 minutes.  The supernatant was drawn off and the tube and its contents 
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were placed in the speedvac® for 5 minutes until dry.  The pellet was then resuspended in 
10µl of ddH2O and the contents were analyzed on an agarose gel for confirmation. 
 The pT-ADV vector was digested with EcoRI.  After the digest 1µl of alkaline 
phosphatase was added.  The vector and alkaline phosphatase was incubated at 37°C in a 
water bath for 1 hour.  After that time 10µl of ddH2O and 2µl  of 3M Na acetate + 66µl  
of 100% ethanol was added.  The contents were mixed by pipetting and placed on dry ice 
for 15 minutes.  After 15 minutes the tube was centrifuged at 4°C at 6,702xg for 10 
minutes.  The ethanol was removed and 1ml of 70% ethanol was added.  The tube was 
inverted once to mix and placed on dry ice for 5 minutes.  The tube was then spun at 4°C 
at 6,702xg rpm for 5 minutes.  The supernatant was drawn off and the tube and its 
contents were placed in the Speedvac® for 5 minutes until dry.  The pellet was then 
resuspended in 10µl of ddH2O and the contents were analyzed on an agarose gel for 
confirmation. 
 PCR product and vector ligation.  In a 0.5ml microfuge tube 1µl of 1/5 dilution 
of prepared pT-ADV, 4µl of PCR product, 1µl of 10 X T4 ligase buffer, 3µl of ddH2O, 
and 1µl of T4 ligase were combined and incubated in a 12°C cooler for 24 hours. 
 Chemical transformations (CaCl2).  E. coli  cells were inoculated into 50ml of 
LB and grown to mid-log.  The cells were then put on ice for 10 minutes and centrifuged 
for at 4°C for 5 minutes at 7,300xg.  The supernatant was decanted, and the cells were 
washed with 50mM CaCl2 and 10% glycerol.  This step was repeated twice more with the 
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final pellet being resuspended in 2ml of CaCl2 and 10% glycerol.  The cells were chilled 
at 4°C for 16 hours,  then divided into 200µl portions and stored at -80°C for future use. 
 The transformation was carried out by allowing 100µl of CaCl2 competent E. coli  
cells to interact on ice for 30 minutes with 3µl of plasmid DNA.  The cells and plasmid 
were then heat-shocked for 50 seconds at 42°C in a water bath.  The mixture was 
subjected to a cold shock on ice for 2 minutes.  500µl of LB were added to the 
transformed cells, which were then plated in 50µl amounts on LB/amp100, IPTG, and X-
gal and grown overnight at 37°C in a Fisher Scientific IsoTemp incubator.  Clones were 
screened using the blue/white method.  The white colonies indicating the interruption of 
the lacZα gene, by the successful inserted PCR product.  Patch plates were made from 
the resulting white colonies and grown overnight as before, and then stored at 4°C 
overnight to verify color. 
Plasmid peparation of clones.  For initial screening a modified version of the 
BioRad plasmid miniprep kit was used, making use of the reagents provided in the kit.  
Patch plates were removed from the 4°C refrigerator and colonies displaying white 
phenotype were selected for inoculation in 5ml of LB/amp100 broth and incubated 
overnight at 37ºµl with aeration.  The tubes of overnight growth were then removed and 
treated as follows.  An aliquot of 1.5ml of the overnight culture was centrifuged 30 
seconds at 13,196xg to pellet the cells.  The supernatant was pipeted off and 200µl of 
BioRad prep kit suspension solution was added and the pellet resuspended.  250µl of 
BioRad lysis solution was then added and mixed by inversion, followed by 250µl of 
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neutralizing solution mixed by inversion.  The chromosomal DNA and cellular debris 
were then centrifuged at 13,196xg for 10 minutes to pellet.  The supernatant was 
collected and the resulting pellet discarded.  700µl of 100% isopropanol was added to the 
supernatant which was then mixed by inversion and allowed to interact for 5 minutes to 
precipitate the plasmid..  Next, the sample was centrifuged for 15 minutes at high speed.  
The supernatant was removed and pellet was washed by 5 minute centrifugation with 1ml 
of ice-cold 70% ethanol.  Ethanol was drained off and pellet was allowed to dry in a 60ºC 
dry incubator.  50µl of 1X TE buffer was added and plasmid was stored in -40º freezer.  
Gel electrophoresis was run on samples (see procedure) using a 1kb marker provided by 
New England Biolabs, and stained with ethidium bromide.  Subsequent purification was 
done using the methods described by Bio-Rad in its midi and miniprep kits. 
 Nuclease digestions.  Digestions were performed in 20µl volumes consisting of 
5µl plasmid sample, 2µl of 10X restriction buffer, 1µl of restriction enzyme, 12µl of 
ddH2O.  All ingredients were combined on ice except the plasmid sample.  The plasmid 
was added last, just prior to placing in the 37º water bath for approximately one hour. 
 Aspartate transcarbamoylase assays.  For the ATCase assay  20ml cell cultures 
were centrifuged during late log phase and washed and resuspended in 5ml of ATCase 
buffer containing 5ml 1M Tris pH 8.0, 200µl 1M beta mercaptoehanol, and 2µl  1M 
ZnSO4 brought to 100ml with ddH2O.  This suspension was then subjected to sonication 
at 4ºC for 4 min.  The following reagents were mixed in the following amounts:  546µl 
ddH2O, 28µl tri-buffer (50mM MES, 100mM diethanolamine, and 51mM N-
ethylmorpholine, pH 9.5), and 35µl  20X aspartate (200mM aspartate).  87µl of this 
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mixture was distributed into each of 6 microtiter wells.  To these wells was added 3µl of 
sample enzyme obtained by sonication.  The reaction was initiated by adding 10µl of 
carbamoylphosphate to each well.  The samples were incubated 20 minutes at 30ºC 
(Adair & Jones 1972).  After incubating, the reaction was stopped by adding 100µl of 
stop mix (2 parts antipyrine and 1 part monoxime, combined just before use).  The 
samples were incubated in the presence of light for a further 2 hours at 60ºC (Prescott & 
Jones 1969).  The samples were then read on the Molecular Devices Company microplate 
reader. 
 Non-denatureing (native) Polyacrylamide gel electrophoresis(PAGE).  To test 
for ATCase activity a native PAGE was run.  The separating gel was prepared by 
degassing a mixture containing 6ml of 30% acrylamide/0.8% bisacrylamide, 3.75ml of 
4X Tris-Cl/SDS pH 8.8 (91g Tris base, 300ml ddH2O, pH adjusted with 1N HCl and 
brought to 500ml with ddH2O), 5.25ml of ddH2O for 5 minutes.  After degassing 0.05ml 
of 10% ammonium persulfate and 0.01ml of TEMED were added and swirled to mix.  
The PAGE apparatus was assembled  and the separating gel solution was added to the 
apparatus with a Pasteur pipet to a height of 11cm.   
 Another Pasteur pipet was used to cover the top of the gel with a 1cm layer of 
H2O-saturated isobutyl alcohol.  Gel was allowed to polymerize for one hour at room 
temperature.  While the gel was polymerizing a stacking gel was made by combining 
0.65ml of 30% acrylamide/0.8% bisacrylamide, 1.25ml of 4X Tris-Cl pH 6.8, and 3.05ml 
ddH2O.  The mixture was degassed for 15 minutes and 25µl of 10% ammonium 
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persulfate and 5µl of TEMED were added.  The solution was mixed by swirling.   The 
alcohol was then poured off of the gel and the top was rinsed with 1Xtris-Cl,  
PH 8.8.  The stacking gel solution was then added and a comb inserted.   The gel was 
allowed to polymerize for 45 minutes. 
 After polymerization, a 1:1 dilution of the sample protein and 2X sample buffer 
was heated for 3 minutes at 100°C in a sealed microcentrifuge tube. The comb was 
removed from the gel and the wells were rinsed with 1X electrophoresis buffer and then 
filled with the same buffer.  The sample was then loaded into the wells, as were the 
standards.  1X electrophoresis buffer was then used to fill in all the empty wells and to 
fill the chamber to the upper electrode. 
The chamber was sealed and connected to the power supply and run at 100 volts until the 
bromphenol blue tracking dye reached the bottom of the separating gel (approximately 1 













Cloning of Bordetella pertussis  pyrB.  To test the Pseudomonas-like aspartate 
transcarbamoylase gene from B. pertussis it was necessary to create a clone from a PCR 
product.  This product was the gene encoding the catalytic subunit pyrB.  The gene 
sequence was ligated onto the pT-ADV at the EcoRI site (Figure 5).  This new plasmid 
(pBPATC2) was  transformed into beta-mercaptoethanol competent E. coli TOP10F’ 
cells and plated on LB with ampicillin at 100µg/ml, IPTG and X-gal (LB amp100 X-gal) 
for blue/white screening.  The resulting white colonies were patch-plated on LB amp100 
X-gal plates and allowed to grow overnight at 37°C.  Multiple patches were selected for 
plasmid isolation.  pBPATC2 was compared by electrophoresis on a 1% agarose gel 
(Figure 6).  Patches number 16 and 17 revealed bands around , 5.6 kb (the approximate 
size of the expected clone).  pBPATC2 was cut with  EcoRI using a 20µl digestion and 
run on a 1% agarose gel for comparison (Figure 7).  Number 17 revealed two bands; one 
around 5 kb (the approximate size of the vector) and one around 1.2kb (expected size of 
the pyrB gene). A sample of clone 17 was sent to Lone Star Labs, Inc in Houston, Texas 
confirming that the cloned DNA fragment was indeed the B. pertussis pyrB gene and in 









   Figure 5.  pT-ADV and the multiple cloning site. 




 ATCase assay of the B. pertussis clone.  The pBATC2 plasmid was transformed 
into E. coli TB2 pyrB- and the modified ATCase Assay (see ATCase assay methods) was 
run.  The assay revealed no ATCase activity.  A native activity gel was performed to 
confirm these findings.  A second ATCase assay was run with pBATC2 transformed into 
E. coli TB2 pyrB- pyrC+.  The expected ATCase activity was not detected in this second 
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 The Bordetella pertussis genome has been sequenced and contains 4,086,186bp.  
The pyrBC’ complex can be found at 324,479bp (Figure 8) with the pyrB portion 
amounting to only 927bp compared to the 1065bp originally suggested.  The difference is 
explained by a misidentified start codon.  The proper start codon is 138bp downstream of 
the earlier misidentified start codon.   However, no appropiate ribosomal binding site was 
found in the vicinity of the pyrB gene.  The adjacent pyrC’ has a premature stop that 
appears to be a nonsense mutation.  When the same region is compared with that of  
Bordetella bronchiseptica and Bordetella parapertussis, the sequence TGA is no longer a 
stop, but is instead TTG.  If indeed the pyrC’  polypeptide performs a scaffolding role in 
the holoenzyme with the pyrB adjacent to it, then the premature stop would likely render 
this gene faulty. 
The pyrBC’  complex is part of a larger operon containing four additional genes.  
These genes were found in the  section of the operon examined.  The examined sequence 
amounted to 3910bp, and neither the beginning nor the end of the operon lay withing this 
sequence.  Thus, it is likely that more genes lie within this  operon.  It should also be 
noted that a search of the genome database revealed no gene that could be identified as 
pyrR..  Overlapping the pyrC’ gene after the early stop is the fourth gene seen in this 


















































Figure 8.  The Bordetella pertussis chromosome and the 
pyrB, pyrBC’, and pyrC genes. 
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and B. parapertussis were not examined to determine if they held the same overlapping 
sequence. 
The presence of the pyrBC’ complex in B. pertussis, B. bronchiseptica, and B. 
parapertussis suggests that the complex existed in a common ancestor.  The premature 
stop mutation found only in  B. pertussis, shows that the mutation occurred sometime 
after the ancestral split.  The fact that the gene was conserved while the ancestor evolved 
into three distinct species, indicates that the gene is still fulfilling some function that the 
organism finds favorable.  How long the pyrBC’ complex with the nonsense mutation is 
maintained in B. pertussis may provide evidence as to whether this mutant gene still 
provides a beneficial product or is now a lost gene.   
 The pBPATC2 failed to complement the pyrB- E. coli TB2 and produce any 
ATCase activity.  This was confirmed by both an ATCase assay and a native PAGE 
activity gel.   It is not know whether this lack of activity is due to the possibility that no 
protein was made, that an inactive trimer was produced, or that inactive monomers were 
produced.  Co-transformation with a plasmid containing pyrC’ from Pseudomonas 
aeruginosa was an afterthought, and should not dissuade one from the idea that the pyrC’ 
from B. pertussis might yet provide the key to the expression of the second ATCase in B. 
pertussis.  The premature stop in the pyrC’ portion of the complex, however, does not 
make this a promising pursuit.     
The logical next step should be the cloning of pyrC’ from B. bronchiseptica or B. 
parapertussis.  The presence of the pyrBC’ complex in these two closely related 
organisms, and the fact that the premature stop is not present in either of their sequences 
 27
make them the obvious choice for pyrBC’ expression in a construct containing the second 
pyrB from B. pertussis. 
A second avenue of exploration is already underway.  Master student Emily 
Carey has been working with the first pyrB gene in B. pertussis (ATC1).  She has cloned 
this gene, and is attempting to make a knockout of that gene for reintroduction into the B. 
pertussis chromosome by homologous recombination.  A wild type B. pertussis with this 
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